Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial. (PubMed, Nat Commun) - Oct 7, 2026 - P1 | "Patients received pre-surgical immune checkpoint blockade (ICB) with dual anti-PD1 nivolumab + anti-CTLA4 ipilimumab (Arm 1), nivolumab alone (Arm 2), or placebo (Arm 3). Higher TIL density and early systemic interferon-signature induction were associated with improved survival, whereas tumor mutational burden was not. Our results demonstrate pharmacodynamic activity of dual ICB in glioblastoma, with survival outcomes comparing favorably to similar studies."
Checkpoint inhibition • Clinical • IO biomarker • Journal • Tumor mutational burden • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CTLA4 • PD-1 • TMB
|
|
Alyssa Russ; Annick D Van den Abbeele; Benjamin M Ellingson; Brenda Acevedo; Catharina Westergaard; David A Reardon; Elisa Aquilanti; Eudocia Quant Lee; Gang Li; Ingo K Mellinghoff; J Ricardo McFaline-Figueroa; Jacqueline Stone; Jessica Wilcox; Jiyoon Kim; Julio C Sánchez; L Nicolas Gonzalez Castro; Lakshmi Nayak; Lauren F Markus; Lauren Schaff; Lu Sun; Maria Lavallee; Michael Lim; Patrick Y Wen; Rameen Beroukhim; Richard G Everson; Robert A Chong; Robert M Prins; Thomas J Lai; Thomas Kaley; Timothy F Cloughesy; Ugonma Chukwueke; Zian Zhuang
|